Integrated diagnosis of glioma based on magnetic resonance images with incomplete ground truth labels

Since the 2016 WHO guidelines, glioma diagnosis has entered an era of integrated diagnosis, combining tissue pathology and molecular pathology. The WHO has focused on promoting the application of molecular diagnosis in the classification of central nervous system tumors. Genetic information such as IDH1 and 1p/19q are important molecular markers, and pathological grading is also a key clinical indicator. However, obtaining genetic pathology labels is more costly than conventional MRI images, resulting in a large number of missing labels in realistic modeling.